Agenus announces five presentations at asco gi highlighting bot/bal activity across colorectal and gastric cancers

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced five presentations featuring botensilimab (bot, an fc-enhanced anti-ctla-4 antibody) plus balstilimab (bal, an anti-pd-1 antibody) at the upcoming american society of clinical oncology gastrointestinal cancers (asco gi) symposium. the conference will take place on january 23-25, 2025, in san francisco, california. the presentations will showcase bot/bal's activity across three distinct co.
AGEN Ratings Summary
AGEN Quant Ranking